» Articles » PMID: 19923463

New Design of MHC Class II Tetramers to Accommodate Fundamental Principles of Antigen Presentation

Overview
Journal J Immunol
Date 2009 Nov 20
PMID 19923463
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Direct identification and isolation of Ag-specific T cells became possible with the development of MHC tetramers, based on fluorescent avidins displaying biotinylated peptide-MHC complexes. This approach, extensively used for MHC class I-restricted T cells, has met very limited success with class II peptide-MHC complex tetramers (pMHCT-2) for the detection of CD4(+)-specific T cells. In addition, a very large number of these reagents, although capable of specifically activating T cells after being coated on solid support, is still unable to stain. To try to understand this puzzle and design usable tetramers, we examined each parameter critical for the production of pMHCT-2 using the I-A(d)-OVA system as a model. Through this process, the geometry of peptide-MHC display by avidin tetramers was examined, as well as the stability of rMHC molecules. However, we discovered that the most important factor limiting the reactivity of pMHCT-2 was the display of peptides. Indeed, long peptides, as presented by MHC class II molecules, can be bound to I-A/HLA-DQ molecules in more than one register, as suggested by structural studies. This mode of anchorless peptide binding allows the selection of a broader repertoire on single peptides and should favor anti-infectious immune responses. Thus, beyond the technical improvements that we propose, the redesign of pMHCT-2 will give us the tools to evaluate the real size of the CD4 T cell repertoire and help us in the production and testing of new vaccines.

Citing Articles

Identification of mouse CD4 T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers.

Bricio-Moreno L, Barreto de Albuquerque J, Neary J, Nguyen T, Kuhn L, Yeung Y Front Immunol. 2024; 15:1329846.

PMID: 38529279 PMC: 10961420. DOI: 10.3389/fimmu.2024.1329846.


Measuring anti-islet autoimmunity in mouse and human by profiling peripheral blood antigen-specific CD4 T cells.

Sharma S, Tan X, Boyer J, Clarke D, Costanzo A, Abe B Sci Transl Med. 2023; 15(703):eade3614.

PMID: 37406136 PMC: 10495123. DOI: 10.1126/scitranslmed.ade3614.


Toward a general model of CD4 T cell subset specification and memory cell formation.

Osum K, Jenkins M Immunity. 2023; 56(3):475-484.

PMID: 36921574 PMC: 10084496. DOI: 10.1016/j.immuni.2023.02.010.


Linked sensitization by memory CD4+ T cells prevents costimulation blockade-induced transplantation tolerance.

Andrade M, Young J, Pollard J, Yin D, Alegre M, Chong A JCI Insight. 2022; 7(11).

PMID: 35674134 PMC: 9220839. DOI: 10.1172/jci.insight.159205.


Hsp90 contains a natural immunogenic I-A-restricted antigen common to rodent and human species.

Enders M, Bayarsaikhan G, Ghilas S, Chua Y, May R, de Menezes M Curr Res Immunol. 2022; 2:79-92.

PMID: 35492393 PMC: 9040146. DOI: 10.1016/j.crimmu.2021.06.002.


References
1.
Chaves F, Richards K, Torelli A, Wedekind J, Sant A . Peptide-binding motifs for the I-Ad MHC class II molecule: alternate pH-dependent binding behavior. Biochemistry. 2006; 45(20):6426-33. DOI: 10.1021/bi060194g. View

2.
Wooldridge L, Lissina A, Cole D, van den Berg H, Price D, Sewell A . Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology. 2009; 126(2):147-64. PMC: 2632693. DOI: 10.1111/j.1365-2567.2008.02848.x. View

3.
Pu Z, Lovitch S, Bikoff E, Unanue E . T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity. 2004; 20(4):467-76. DOI: 10.1016/s1074-7613(04)00073-1. View

4.
Murphy K, Heimberger A, Loh D . Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science. 1990; 250(4988):1720-3. DOI: 10.1126/science.2125367. View

5.
Pahler A, Hendrickson W, Kolks M, Argarana C, Cantor C . Characterization and crystallization of core streptavidin. J Biol Chem. 1987; 262(29):13933-7. View